ArticleOncotarget2017

Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer.

Tongtong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.